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In vitro circumvention of cisplatin resistance by the
novel sterically hindered platinum complex AMD473
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1CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK; 2JOhnson Matthey Technology Centre,
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Summary A novel sterically hindered platinum complex, AMD473 [cis-amminedichloro(2-methylpyridine) platinum (II)], has been selected for
phase clinical trials due to commence in 1997. AMD473 was rationally designed to react preferentially with nucleic acids oversulphur ligands
such as glutathione. This report documents the in vitro circumvention of acquired cisplatin resistance mechanisms in human ovarian
carcinoma (HOC) cell lines by AMD473. In a panel of 11 HOC cell lines, AMD473 showed intermediate growth inhibition potency (mean IC50
of 8.1 ,UM) in comparison to cisplatin (mean IC50 of 2.6 ,UM) and carboplatin (mean IC50 of 20.3giM). AMD473 showed only a 30.7-fold increase
in IC50 value from the most sensitive to the most resistant HOC cell line, whereas forcisplatin it was 117.9-fold and for carboplatin 119.7-fold.
AMD473 also showed significantly (P< 0.05) reduced cross-resistance to cisplatin in a panel of three cell lines with known acquired platinum
drug resistance mechanisms (mean RF for AMD473 was 1.9, for cisplatin 9.1). Cellular accumulation of AMD473 was not reduced in two
HOC cell lines (A2780cisR and 41McisR), in which reduced cisplatin accumulation is a major mechanism of acquired cisplatin resistance.
AMD473 naked-DNA binding was significantly less affected (P < 0.05) than that of cisplatin by the presence of 5 mm glutathione. Also,
AMD473 almost completely circumvented acquired cisplatin resistance in a cell line (A2780cisR) with fivefold elevated intracellular
glutathione levels compared with the parent A2780 cell line when measured by clonogenic assay (RF 4.5 forAMD473 vs RF 18 forcisplatin).
AMD473 also showed a lower increase in IC5 than cisplatin in an A2780 cell line model with artificially elevated glutathione levels. AMD473
DNA binding was slower than that of cisplatin on both naked and cellular DNA. AMD473 also formed DNA interstrand cross-links (ICLs) at a
slower rate than cisplatin (peak ICL formation was at 5 h for cisplatin vs 2 14 h for AMD473) after equitoxic doses were exposed to HOC cells
for 2 h. AMD473 ICLs in the CH1 HOC cell line were slowly formed and showed no visible signs of being repaired 24 h after removal of drug.
This was paralleled by a slower, longer lasting induction of p53 protein by equitoxic doses of AMD473 in HOC cell lines with wild-type p53.
This new class of sterically hindered platinum compound, selected for clinical trial in 1997, may therefore elicit improved clinical response in
intrinsically and acquired cisplatin-resistant tumours in the clinic.
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Anti-cancer drugs based on and including cisplatin are in wide-
spread use for the treatment oftesticular, ovarian, small-cell lung,
bladder, cervical and head and neck carcinomas. While being very
effective in some tumour types, such as testicular carcinomas
(Loehrer et al, 1984), cisplatin suffers from two major drawbacks,
which are severe normal tissue toxicity and the frequent occur-
rence ofinitial and acquired resistance to treatment (Yarbo, 1992).
To date, the only noticeable improvement that has been made in
overcoming cisplatin resistance has been by platinum complexes
containing the 1,2-diaminocyclohexane (DACH) ligand
(Burchenal et al, 1979), although several clinical cases of unac-
ceptable toxicity have led to the discontinuation of some platinum
agents carrying this ligand (Canetta et al, 1990).
Ourplatinum-based drug discovery programme in collaboration
with the Johnson Matthey Technology Centre (and, in part, with
Bristol Myers Squibb) has thus far resulted, firstly, in the
successful worldwide introduction of the less toxic cisplatin
analogue carboplatin (Paraplatin) (Harrap, 1985), secondly, the
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discovery of the ammine/amine platinum(IV) dicarboxylates
(Kelland et al, 1992), which led to the introduction of the first
orally bioavailable platinum complex JM216 [bis-acetato-
ammine-dichloro-cyclohexylamine platinum(IV)], now in phase II
clinical trial (Kelland et al, 1993a; McKeage et al, 1995), and,
more recently, the identification of the first trans-platinum
complex possessing in vivo anti-tumour activity against a range of
murine and human tumour models [JM335, trans-ammine(cyclo-
hexylaminedichlorodihydroxo) platinum(IV)] (Kelland et al,
1994, 1995; Goddard et al, 1996). However, while carboplatin
(and JM216) have made (or may make) a substantial impact in
improving quality of life for patients undergoing platinum-based
chemotherapy, there remains an overwhelming need to broaden
the activity of platinum-based drugs to induce responses against
currently resistant tumours.
In response to the great need for new anti-cancer drugs capable
of circumventing innate and acquired resistance, the novel
platinum-based compound AMD473, a.k.a. JM473 (Figure 1), has
been developed at the Institute of Cancer Research, in collabora-
tion with the Johnson Matthey Technology Centre/AnorMED.
Tumour resistance to platinum anti-cancer drugs has been shown
to be due to one or more of the following mechanisms: reduced
accumulation, increased cytoplasmic detoxification by cellular
thiols or increased DNA repair/tolerance of platinum-DNA
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adducts (Kelland, 1993). AMD473 was designed specifically to
circumvent thiol-mediated drug resistance by sterically hindering
its reaction with glutathione (GSH) while still retaining the ability
to form cytotoxic lesions with DNA (Holford et al, 1996). The
introduction of steric bulk at the platinum centre (using 2-
methylpyridine) predicts a dissociative mechanism of substitution
rather than the associative mechanism that predominates with
cisplatin.
This study reports on the in vitro cytotoxic properties of
AMD473, mainly with regard to the circumvention of acquired
cisplatin resistance in three paired cell line models with previously
determined mechanisms of resistance: 4IM/4IMcisR (resistance
predominantly due to reduced drug accumulation) (Loh et al,
1992; Sharp et al, 1995), CH1/CHlcisR (resistance due to
increased DNA damage repair/tolerance) (Kelland et al, 1992b;
O'Neill et al, 1995) and A2780/A2780cisR (resistance due to
elevated glutathione levels, reduced drug accumulation and
increased DNA damage repair/tolerance) (Behrens et al, 1987;
Johnson et al, 1994; Kelland et al, 1994). AMD473 has been
selected for phase I clinical trials in the UK, which are due to
commence in 1997.
MATERIALS AND METHODS
Platinum drugs and other chemicals
Cisplatin, carboplatin, JM216, JM335, AMD473 [cis-
amminedichloro(2-methylpyridine) platinum (II)], AMD494
(unsubstituted pyridine) and AMD508 (2,6-dimethylpyridine)
(Figure 1) were synthesized by and obtained from the Johnson
Matthey Technology Centre (Reading, Berkshire, UK). All other
chemicals were obtained from Sigma Chemicals (Poole, UK)
unless otherwise stated.
Cell culture
A panel of 11 parent human ovarian carcinomas (SKOV-3, OV1-P,
A2780, HX/62, PXN94, CHI, 41M, OVCAR3, LK1, LK2 and
PAl) and acquired cisplatin (cisR)-resistant sublines (A2780cisR,
4lMcisR, CHlcisR) were used in this study (Hills et al, 1989;
Kelland et al, 1993a; Mellish et al, 1994). Cells were maintained
free ofMycoplasma and were grown as monolayers in Dulbecco's
Modified Eagle Medium supplemented with 10% fetal calf serum
(Imperial Laboratories, Andover, UK), 2 mM L-glutamine and
0.5 ,ug ml-1 hydrocortisone in a humidified 6% carbon dioxide,
94% air atmosphere.
Growth inhibition assay
Growth inhibition by platinum agents was measured using the
sulphorhodamine B (SRB) assay (Skehan et al, 1990). Between
3000 and 8000 cells, dependent upon the growth characteristics of
the cell line, were seeded into the wells of 96-well plates and
allowed to attach overnight. Serial dilutions of platinum drugs
were then added to quadruplicate wells and the plates then left to
incubate in normal growth conditions for 96 h. Plates were then
fixed with 10% trichloroacetic acid and stained with SRB. Basic
amino acid content in each well was measured after solubilizing
the SRB stain in 10 mM Tris using a Titertek Multiscan MCC/340
MKII plate reader set at 540 nm. Mean absorbance for each drug
dose was expressed as a percentage of the control untreated well
absorbance and plotted vs drug concentration. IC50 concentrations
are the drug concentrations that reduced the mean absorbance at
540 nm to 50% ofthose in the untreated control wells.
Modulation of intracellular glutathione levels
The intracellular GSH content of the A2780 ovarian carcinoma
cell line was artificially elevated by exposing cells in 96-well
plates to 5 mm glutathione ethyl ester for 4 h (Versantvoort et al,
1995). Extracellular GSH ester was removed by washing with
phosphate-buffered saline (PBS). Cells were then instantly
exposed to platinum agents for 2 h followed by incubation in drug-
free growth medium forafurther94 h. IC50 values forcisplatin and
AMD473 were then determined as in the above SRB assay.
Approximately 1 x 106 A2780 ovarian carcinoma cells seeded in
T25 tissue culture flasks were treated with GSH ester in an iden-
tical way and measured for relative intracellular GSH content by
flow cytometry using monobromobimane fluorescence as an indi-
cator ofrelative GSH (Hedley and Chow, 1994).
Clonogenic survival assay
Triplicate T25-cm2 tissue culture flasks were seeded with approxi-
mately 400 cells from a single-cell suspension (A2780 and
A2780cisR HOC cells) perdrug concentration tested. This number
of cells has been previously shown to yield approximately 200
individual colonies ofcells per flask. Cells were then left to attach
for 24 h, after which time they were treated with eithercisplatin or
AMD473 for 2 h. Drug was then washed out gently with PBS, and
the cells re-fed with fresh growth medium. After the cell colonies
had reached a size ofapproximately 50 cells (normally 7-9 days),
the flasks were fixed with 50% methanol containing methylene
blue. The number of colonies per flask were then counted and
expressed as a percentage ofthe number ofcolonies in the control
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Figure 1 Structures of the platinum complexes cisplatin, carboplatin,
JM216, JM335, AMD473, AMD494 and AMD508
British Journal ofCancer (1998) 77(3), 366-373 0 CancerResearch Campaign 1998368 J Holford etal
100
10
8
ai
41M A2780 CHI OVP-1
z | ; r_ 9" gH
u | s I
_.
H
_ r ____
B - i! B
S S
c > -. H t_| ,__ ___ i__i_ 1111111_T|| -115J _-I,3E31 raaa ESS _H_ffl_Hi_-H : 5-3_ --.--
1- ' 1-i-11 B
PXN94 HW62 SKOV-3 OVCAR-3 LK1 LS PS
Cell line
Figure 2 Sulphorhodamine B assay IC50 profiles for cisplatin (O), carboplatin (m) and AMD473 (N) in a panel of human ovarian carcinoma cells. Drug
exposure was for 96 h. Columns represent mean from at least three experiments; bars represent s.e.m.
untreated flask. Clonogenic survival assay IC50 values are the drug
concentrations that caused a 50% reduction in the number of
colonies formed compared with untreated cells.
Platinum drug accumulation measurement
Exponentially growing cells were treated in triplicate with plat-
inum drugs in fresh growth medium. After 2 h of exposure, drug
was removed and the cells washed twice with ice-cold PBS. Cells
were then harvested in 500 ,l of ice-cold PBS and gently soni-
cated on ice. Aliquots (50gl) were then added to 200 ,l of 1 M
sodium hydroxide, left overnight at 37°C and the protein content
measured (Lowry et al, 1951). The remainder ofthe sonicated cells
were then analysed by flameless atomic absorption spectropho-
tometry (FAAS) for platinum content using Perkin Elmer
models HGA700 and 1IOOB. FAAS has been shown to have a
detection limit of approximately 5 ng (1 nmol) platinum. Then,
nmol platinum mg-' protein was plotted vs concentration of plat-
inum drug exposed to the cells. This method has been previously
validated and been shown to produce less than 15% variability
between and within experiments (Mellish et al, 1995).
Reactivity of platinum complexes with salmon sperm
DNA
In the presence and absence of 5 mm glutathione (reduced form)
100 gM solutions of cisplatin and AMD473 were incubated at
37°C with 0.5 mg ml-l salmon sperm DNA dissolved in TE buffer
(10 mm Tris, 1 mm EDTA, pH 8). Reactions were allowed to
proceed for predetermined lengths oftime and then terminated by
ethanol precipitation and washing in 70% ethanol. DNA samples
were redissolved in TE buffer and DNA content was quantified by
measuring absorbance at 260 nm using a 1 cm pathlength quartz
cuvette with a Perkin Elmer Lambda 7 UVNVIS spectropho-
tometer. DNA concentration was calculated as A260 x 50 ,ug ml-'.
A26/A280 ratios were 1.8 for all samples. Platinum content ofDNA
samples was measured by FAAS as above. Platinum content per g
ofDNA was plotted vs time.
Cellular DNA platination
Exponentially growing cells (approximately 3 x 107) were treated
with drug in normal growth medium, varying both length of time
of exposure to drug and concentrations of drug used. Cells were
harvested and washed twice in ice-cold PBS. DNA was then
extracted from the cell pellet (Miller et al, 1988). DNA extracts
were then treated with RNAase for 1 h at 37°C and precipitated
and washed in 70% ethanol. Pellets were dissolved in 500gl ofTE
buffer overnight and nm platinum per g of DNA was measured as
in the salmon sperm DNA binding assay. A2J/A280 ratios were
between 1.75 and 1.8 for all samples.
Alkaline elution
The ability of platinum compounds to form DNA interstrand
cross-links in HOC cells were measuredby alkaline elution (Kohn,
1987).'4C-thymidine-labelled test cells were exposed to cisplatin
and AMD473 in normal growth media, harvested, washed in ice-
cold PBS and irradiated on ice with 5 Gy using a 2000 Ci 6OCo
source. An untreated control flask containing '4C-thymidine-
labelled cells was also included in the tests.3H-thymidine-labelled
cells were used as an internal standard (these were irradiated on ice
with 1.5 Gy using a 2000 Ci 6"Co source for 1.5 min to introduce
DNA single-strand breaks). Results were plotted as the fraction of
'4C-thymidine-labelled DNA retained vs the fraction of 3H-thymi-
dine-labelled internal standard DNA retained. DNA interstrand
cross-link (ICL) index was calculated using the formula: (1 - rJ
1 - r)"2 - 1, as previously described (Kohn, 1987), where r and
ro are the fractions of '4C-thymidine-labelled DNA for treated
vs control cells remaining on the filter when 30% of the 3H-
thymidine-labelled DNA is retained on the filter.
Western blotting
Cells were washedin PBS and then harvestedby trypsinization at0,
6, 12, 24, 48, 72 and 96 h after drug treatment. Cleared cell lysates
were produced and electrophoresed down a 8-16% SDS-PAGE
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Figure 3 Cross-resistance profiles for 41McisR vs 41 M, CHlcisR vs CH1
and A2780cisR vs A2780 (all ovarian carcinoma) for cisplatin (U), carboplatin
(0), JM216 (n), JM335 (O) and AMD473 (M). Drug exposure was for 96 h.
Columns represent mean from three or four experiments; bars represent
s.e.m.
gradient gel (Sharp et al, 1995). Proteins were then electroblotted
onto a nitrocellulose filter (Millipore, Watford, UK) (Towbin et al,
1979) in transfer buffer containing 10% methanol at 300 mA for
2 h at 4°C. The nitrocellulose filter was then blocked in PBS
(pH 7.6) containing 0.5% casein overnight at 4°C. p53 protein
was detected using a mouse primary monoclonal antibody (DO1,
Santa Cruz Biotechnology, Santa Cruz, CA, USA). A horseradish
peroxidase-labelled anti-mouse monoclonal secondary antibody
combined with enhanced chemiluminescence reagents (Amersham,
Buckinghamshire, UK) and exposure to film (Hyperfilm-ECL,
Amersham) was used to visualize protein bands.
Statistical analysis
When appropriate, statistical significance was tested using a two-
tailed Student's t-test. All values shown are mean values with the
corresponding standard error ofthe mean.
RESULTS
In vitro growth inhibition
Across the panel of 11 'parent' HOC cell lines, AMD473 showed
intermediate potency between cisplatin and carboplatin at
inhibiting growth over a 96 h exposure period (AMD473 mean
IC50 8.1 ± 3.6 gM, cisplatin mean IC50 2.6 ± 1.4 gM, carboplatin
mean IC50 20.3 ± 10.1 gM) (Figure 2). However, the increase in
IC50 value from the most sensitive cell line to the most resistant
was much lower for AMD473 (AMD473, 30.7-fold; cisplatin,
117.9-fold; carboplatin, 119.7-fold). While IC50 values determined
for AMD473 and AMD494 were similar, AMD508 was approxi-
mately threefold less potent (data not shown). The pattern of
response across the cell line panel was similar for all platinum
drugs tested, with SKOV-3 and HX62 being most resistant
whereas CH1, LK1 and LK2 were relatively sensitive. Pearson
coefficient COMPARE analysis resulting from in vitro data using
the National Cancer Institute 60 cell line panel indicated that
AMD473 did not share a response pattern with any other agent in
the databank (highest GI50 coefficient being 0.607 for chloram-
bucil) (personal communication, National Cancer Institute).
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Figure 4 Clonogenic survival curves for cisplatin (A) and AMD473 (B) in
A2780 (-) and A2780cisR (A) after a 2-h exposure to drug. All values
represent means from three experiments; bars represent s.e.m.
Comparative cross-resistance profiles for AMD473, cisplatin,
carboplatin, JM216 and JM335 using the 41M/41McisR,
CHI/CHlcisR and A2780/A2780cisR pairs are shown in Figure 3.
The A2780cisR/A2780 comparison is of special interest for
AMD473 as A2780cisR possesses significantly higher GSH levels
than the respective parental line (42 ± 15 vs 7.8 ± 0.7 nmol mg-'
protein respectively) (Kelland et al, 1992). Notably, the resistance
factor (RF, IC50 resistant/parent line) of 2 ± 0.3 for AMD473 for
this pair of cell lines was the lowest ofthe lead series ofplatinum
complexes investigated (the next lowest being 4.5 for JM216) and
was significantly lower (P < 0.05) than that observed for cisplatin
itself, carboplatin orJM335. The resistance factorfor the unsubsti-
tuted pyridine complex AMD494 in A2780cisR/A2780 was also
higher (3.5) than that observed for either AMD473 or AMD508
(RF of2.2) (data not shown). Further, AMD473 also circumvented
acquired cisplatin resistance in other cell line pairs in which
elevated GSH was not involved in the resistance mechanism:
41M/4lMcisR, RF of 1.3 ± 0.15, resistance due to reduced
drug transport; and CHI/CHlcisR, RF of 2.5 ± 0.7, resistance
due to enhanced DNA repair and/or increased tolerance to plat-
inum-DNA adducts. AMD473 produced similar circumvention of
cisplatin resistance in the same cell line models after 2 h drug
exposures in the SRB assay (Holford et al, submitted, 1997). In
addition, no cross-resistance was observed in a P-glycoprotein
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Figure 6 Naked-DNA binding rates for 100gM cisplatin (-, E) and 100gM
AMD473 (0, 0) in the presence (empty symbols) and absence (solid
40 50 60 symbols) of 5mm reduced GSH. All values represent means from three
experments; bars represent s.e.m.
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Figure 5 Platinum drug accumulation for cisplatin (U, O) and AMD473
(0, 0) in two pairs of human ovarian carcinoma cell lines. (A) A2780 (filled
symbols)/A2780cisR (empty symbols) pair of HOC cells. (B) 41M (filled
symbols)/41 McisR (empty symbols) pair of HOC cell lines. Drug exposure
was for 2 h. All values repesent means from four experiments; bars represent
s.e.m.
overexpressing acquired doxorubicin-resistant subline of the CHI
cell line (data not shown).
Clonogenic survival
AMD473 was less potent at inhibiting A2780 and A2780cisR
HOC cell colony formation than cisplatin when cells were
exposed to these agents for 2 h (AMD473, IC50 14 ± 0.7 gM and
63 ± 3.0 gM for A2780 and A2780cisR respectively; cisplatin,
IC50 2.5 ± 0.15 gM and 45 ± 1.9 gM for A2780 and A2780cisR
respectively) (Figure 4). As in the SRB growth inhibition assay,
AMD473 showed significant circumvention of acquired cisplatin
resistance in the A2780cisR cell line (RF 4.5 ± 0.06 for AMD473
vs 18 ± 1.8 for cisplatin, P < 0.05).
Drug accumulation
Cellularcisplatin accumulation was reduced (2.4-fold ± 0.23) in the
A2780cisR cell line vs its parent cell line A2780 (Figure 5A). The
cellular accumulation ofAMD473 was equal in both the A2780 and
the A2780cisR cell lines and at equimolar concentrations was
greater than the uptake of cisplatin in the A2780 parent cell line.
Significantly more AMD473 than cisplatin was accumulated in the
A2780cisR cell line when equimolar concentrations of drug were
exposed to the cells (P < 0.05). The41McisR acquired resistant cell
line also reduced cisplatin accumulation compared with the 41M
CH1 CHlcisR A2780 A2780cisR
Cell line
Figure 7 Cellular DNA platination levels of cisplatin (U) and AMD473 (S)
in human ovarian carcinoma cell lines after a 2-h exposure to 100 gM drug.
Columns represent means from three or four experiments; bars represent
s.e.m.
parent cell line (mean 4.7-fold ± 0.46, Figure SB). AMD473
accumulation was equal in the 41M and 4lMcisR cell lines.
Significantly more AMD473 than cisplatin was accumulated in the
41McisR subline at equimolar concentrations (P < 0.05). For both
cisplatin and AMD473, cellulardrug accumulation increased with a
linear relationship to the amount ofdrug exposed to the cells.
Effect of elevated cellular GSH on growth inhibition
The A2780 HOC cell line was used as a model to examine the
effect of artificially elevating intracellular GSH levels as its
cisplatin-resistant subline, A2780cisR, contains approximately
five times higher levels of intracellular GSH. When measured by
flow cytometry, GSH ester-treated A2780 cells contained signifi-
cantly higher (2.1-fold, P = 0.01) intracellular GSH levels than
untreated cells. AMD473 growth-inhibitory potency was less
affected by elevated GSH levels than that ofcisplatin. Cisplatin 2-
h exposure IC50 was increased 2.2 ± 0.3-fold, whereas the 2-h IC50
of AMD473 was increased by only 1.6 ± 0.1-fold. The P-value
was 0.05, bordering on statistical significance (n = 4).
Naked DNA binding
AMD473 shows significantly (P < 0.05 for all time points)
reduced reactivity with salmon sperm DNA compared with
equimolar concentrations ofcisplatin (Figure 6). The difference in
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Figure 8 Alkaline elution data from A2780 (A) and CH1 HOC cells (B).
(A) ICL index in A2780 cells was calculated as described and plotted vs time
after a 2-h exposure to equitoxic (5 x 2-h IC.) concentrations of 28.5 gM
cisplatin (M) and 162 gM AMD473 (A). (B) ICL index in CH1 cells was
calculated as described and plotted vs time after a 2-h exposure to equitoxic
(5 x 2 h IC.), concentrations of 13.5 gM cisplatin (O) and 134.5 gM AMD473
(A). All data shown represent means from three experiments; bars represent
s.e.m.
DNA binding for the two platinum compounds became less with
time - the rate ofcisplatin platination decreasing from 2 to 4 h and
increasing for AMD473. This suggests that the cisplatin-DNA
reaction had begun to reach equilibrium at this point and that
AMD473 DNA binding shows a lag period due to its slower aqua-
tion rate in aqueous solution (aquation rate in water = 1.47 ± 0.32
x 10-5 s-' for AMD473 vs 2.98 ± 0.6 x 10-5 s-I for cisplatin) and
reduced overall reactivity with hard nucleophiles, such as DNA
bases (Holford et al, 1996). Neither cisplatin nor AMD473 DNA
binding rates were affected by the presence of 500 ,UM reduced
GSH (data not shown). However, in the presence of5 mm reduced
GSH, cisplatin showed approximately 50% lower platination
levels on the DNA compared with the reaction without reduced
GSH at 1, 2 and 4 h. AMD473 DNA binding was significantly less
affected than cisplatin in the presence of 5 mm GSH at the 1- and
2-h time points (P < 0.05), but did show a 40% reduction in DNA
binding rate after 4 h compared with the reaction without GSH.
Cellular DNA platination
Platination of CH1, CHlcisR, A2780 and A2780cisR HOC cell
line DNA by 100 gM AMD473 and cisplatin is summarized in
Figure 7. DNA in all cell lines tested was platinated by cisplatin
and AMD473 in a concentration- and time-dependent manner.
Over an 8-h time course, the DNA platination rate for 100 gM
cisplatin in the CHI HOC cell line was 225 nmol Pt g-' DNA h-'
Figure 9 p53 induction vs time after 2-h equitoxic (2-h IC50) exposure to
cisplatin (upper panels) and AMD473 (lower panels) in A2780 and CH1 HOC
cells. Note, A2780 p53 induction was only measured up to 72 h, as past this
time point cell growth was restricted by confluence
vs 92.5 nmol Pt g-' DNA h-1 for 100 gM AMD473. In the CHlcisR
subline, DNA platination by cisplatin orAMD473 was not signifi-
cantly different to that in the parent CHI cell line. In the
A2780cisR subline, DNA platination by cisplatin was reduced to
40% of that in the parent cell line, which is attributed to reduced
drug accumulation as well as metabolism by intracellular thiols.
AMD473 DNA binding was also reduced in the A2780cisR
subline, butonly to 68% ofthat in the parent A2780 cell line. This
reduction in DNA binding must be wholly attributed to intra-
cellular metabolism, as AMD473 accumulation in the A2780 and
A2780cisR cell lines have been shown to be equal.
Alkaline elution
Cisplatin and AMD473 both formed DNA interstrand cross-links
(ICLs) in all HOC cell lines tested (Figure 8). In the A2780 cell
line (Figure 8A), cisplatin DNA ICL formation peaked at 5 h after
drug exposure and was then rapidly repaired. An equitoxic
concentration of AMD473 (5 x 2-h IC50 concentration) formed
DNA ICLs at a slower rate than cisplatin, peaking at 14 h. In the
CHI HOC cell line (Figure 8B), cisplatin also formed maximal
levels of ICLs at 5 h, which were then rapidly repaired. Once
again, equitoxic concentrations of AMD473 formed ICLs at a
slower rate than cisplatin with maximal levels still not being
reached 24 h after drug incubation. No significant removal of
AMD473 ICLs was observed in the CHI cell line 24 h after drug
incubation. DNA fragmentation due to cell death 24 h after drug
incubation made measurements ofICL levels after this time unre-
liable. The different kinetic patterns observed between A2780 and
CHI for AMD473 ICL formation and removal may be related to
the different cell-doubling times for these two cell lines, i.e.
A2780 with the faster cell-doubling time of 12.7 h may be forced
to repair AMD473 cross-links more rapidly than the slower
growing CHI HOC cell line (doubling time 23.7 h). The differ-
ence in AMD473 ICL formation may also be related to repair
capability, although both cell lines had a similar pattern for forma-
tion and removal ofcisplatin ICLs.
p53 induction
p53 induction was measured as a relative index of DNA damage
by cisplatin and AMD473 over a time course. CHI and A2780
HOC cells (wild type for p53) (Walton et al, 1995) displayed
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different kinetic patterns of p53 induction by cisplatin and
AMD473 when exposed to equitoxic concentrations. Cisplatin p53
induction was comparatively faster than that ofAMD473, but was
not as long-lasting, as shown in Figure 9. In the A2780 cell line,
peak p53 induction occurred 12 h after exposure to cisplatin (2-h
IC50 concentration for 2 h). An equitoxic dose of AMD473
produced peak p53 induction after 24 h in the A2780 cell line. In
the CHI cell line, p53 induction by cisplatin peaked at 6 h after
drug exposure and remained at high levels ofexpression until 48 h
after drug exposure, after which the p53 protein levels decreased
slowly. As with ICL formation, AMD473 p53 induction in the
CHI cell line was biphasic in nature, with only weak induction of
p53 protein visible for the first 24 h after drug exposure. At 48 h
after drug exposure, p53 protein was more highly induced and
peaked at 72 h after drug exposure.
DISCUSSION
From over 500 compounds studied in a collaborative effort
between the CRC Centre for Cancer Therapeutics at the Institute
of Cancer Research (Sutton, UK) and the Johnson Matthey
Technology Centre, the following lead platinum complexes have
emerged: carboplatin, the only cisplatin analogue to be registered
worldwide (Harrap, 1985); JM216, now in phase II clinical trial as
the first orally bioavailable platinum drug (Kelland et al, 1993);
JM335, the first trans-platinum analogue to demonstrate attractive
in vivo anti-tumour activity against a range of s.c. preclinical
tumour models (Kelland et al, 1994); and, herein, the sterically
hindered complex AMD473. In contrast to the development of
carboplatin and JM216, which was predominantly on the basis
of improving patient life quality during platinum-based
chemotherapy, AMD473 was designed in recognition of an
increasing awareness ofthe mechanisms by which tumours might
become resistant to cisplatin/carboplatin in the clinic. Selection of
AMD473 from the series of novel sterically hindered platinum
compounds for clinical development was based on its superior
cross-resistance profile to that of AMD494 and its superior
potency over AMD508.
Reduced cisplatin accumulation (Gately and Howell, 1993)
increased intracellular thiols, such as glutathione (Pendyala et al,
1995) and metallothionein (Kasahara et al, 1991), and repair/toler-
ance of drug-DNA lesions (Calsou et al, 1993; Mamenta et al,
1994) are regular features ofintrinsic and acquired cisplatin resis-
tance. Therefore, new platinum agents capable of improving clin-
ical response to tumours and increasing long-term patient survival
mustbe capable ofcircumventing at leastoneofthese mechanisms
ofresistance. As GSH has now been implicated in the regulation of
drug transport in GS-X pump and multidrug resistance-associated
protein (MRP)-overexpressing tumour cell lines (Ishikawa et al,
1994; Versantvoort et al, 1995) and may possibly play a role in
DNA repair (Lai et al, 1989), it appeared that reducing the reac-
tivity of platinum agents with glutathione may be the key to
improved response in resistant tumours. Recently, it has been
shown that head and neck cancer patients with low glutathione S-
transferase (GST) activity are 4.7 times more likely to respond to
platinum-based chemotherapy than those with higher levels of
GST (Nishimura et al, 1996).
In view of the above evidence, attempts were made to introduce
steric bulk at the platinum centre using heterocyclic ligands with
substituents onthering atomnexttothe ligand atom so as topreclude
access of sulphur. Such compounds should favour a dissociative
mechanism of substitution. With relatively unhindered molecules,
such as cisplatin, the associative mechanism predominates and
preferential reaction with sulphurdonors, e.g. glutathione, occurs. In
addition, the favourable anti-tumour properties previously observed
with ammine/amine complexes compared with bis-ammine or bis-
amine complexes (Kelland et al, 1992a) were retained. The resulting
complex containing a 2-methylpyridine ligand, AMD473, possesses
the predicted chemical properties in being significantly less suscep-
tible to inactivation by sulphur-containing soft nucleophiles
compared with cisplatin (Holford et al, 1996). In addition, the resis-
tance factor for AMD473 in an acquired cisplatin-resistant human
ovarian carcinoma cell line known to possess elevated GSH levels
was significantly lower than that obtained for cisplatin, carboplatin,
JM335 andJM216. Also, AMD473 showedencouraging circumven-
tion ofacquired cisplatin resistance in human ovarian carcinoma cell
lines in which resistance was attributable to reduced drug transport
(41McisR) or enhanced DNA repair/increased tolerance of plat-
inum-DNA adducts (CHlcisR).
The ability of AMD473 to circumvent the mechanisms of
reduced cisplatin accumulation in the cisplatin-resistant cell lines
could be due to reduced formation ofglutathione-drug complexes
and subsequent efflux through a glutathione complex-dependent
transporter, e.g. GS-X pump (Ishikawa et al, 1994) or to the
increased lipophilicity of AMD473 over cisplatin, which may
enable it to cross the plasma membrane more freely than cisplatin,
as in the case of JM216 (Sharp et al, 1995). How AMD473 may
circumvent resistance at the level ofDNA damage repair/tolerance
is a complex matter and could be explained by many mechanisms.
However, the observation that AMD473 bifunctional cross-links
may be formed and removed over a longer period of time than
those produced by cisplatin may be important. Subsequent delayed
and extended induction ofp53 proteinby AMD473 compared with
equitoxic doses of cisplatin may be directly related to the time
course of bifunctional adduct formation and removal. Therefore,
platinum agents that form bifunctional adducts over a long time
course, such as AMD473, may stimulate p53 and other down-
stream DNA damage-responsive elements, such as gaddl53,
gadd45, p21 andc-jun (Delmastro et al, 1997), over longerperiods
of time, which may alter cellular responses to the DNA damage
produced by AMD473 vs cisplatin.
In summary, partial and complete circumvention of acquired
platinum drug resistance combined with the mechanistic data in
this report suggest that AMD473 is a promising candidate for
further evaluation in vivo and in the clinic. In addition, AMD473
has been shown to possess improved activity over that ofcisplatin
in vivo in some human ovarian carcinoma xenograft models
(Kelland et al, 1996). AMD473 has now been approved forphase I
clinical trials by the UK CRC Phase I/II committee, begining in
October 1997.
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